{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-22-001806","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.483572+00:00","generated_at":"2026-06-23T23:45:29.864095+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lexaria receives positive FDA pre-IND response for DehydraTECH-CBD hypertension program","bullets":["FDA agreed to 505(b)(2) NDA pathway, typically enabling faster commercial approval.","Proposed Phase Ib protocol for 100 hypertension patients received favorably by FDA.","FDA confirmed no additional non-clinical studies required before IND initiation.","Lexaria can now work towards opening IND and full registration of DehydraTECH-CBD."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-22-001806","json":"https://secwatch.observer/filing/0001640334-22-001806.json","markdown":"https://secwatch.observer/filing/0001640334-22-001806.md","text":"https://secwatch.observer/filing/0001640334-22-001806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033422001806/0001640334-22-001806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033422001806/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:45:29.864095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}